US Stock Market Move | KLA Corporation (KLAC.US) tumbles 10% as its performance guidance for the third quarter of the 2026 fiscal year falls below expectations.
On Friday, KLA Corporation (KLAC.US) plummeted 10% to $1513.01.
On Friday, KLA Corporation (KLAC.US) fell by 10%, closing at 1513.01 US dollars. In terms of news, KLA announced revenue of 3.3 billion US dollars for the second quarter of the 2026 fiscal year ending on December 31, 2025, with an adjusted earnings per share of 8.85 US dollars, both surpassing market expectations. However, the performance guidance for the third quarter did not meet market expectations. The company's guidance for the third quarter indicated revenue of 3.35 billion US dollars with a fluctuation of 150 million US dollars. The non-GAAP diluted earnings per share are expected to be around 9.08 US dollars with a fluctuation of 0.78 US dollars. This guidance did not meet market expectations for accelerated growth. The moderate growth rate did not reflect a strong acceleration trend driven by artificial intelligence.
Market analysis widely believes that the deviation phenomenon of "positive earnings but falling stock prices" this time is mainly due to investors' concerns about the historically high valuation of KLA, as well as caution about the company's revenue growth rate slowing down for three consecutive quarters.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


